For the quarter ending 2026-03-31, ALDX has $66,483,081 in assets. $24,326,289 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Marketable securities | - | 0 | 15,956,740 | 40,678,370 |
| Cash and cash equivalents | 65,002,305 | 70,041,254 | 59,340,599 | 41,241,269 |
| Prepaid expenses and other current assets | 1,271,514 | 1,742,202 | 2,162,696 | 2,638,589 |
| Total current assets | 66,273,819 | 71,783,456 | 77,460,035 | 84,558,228 |
| Deferred offering costs | - | 0 | 0 | 0 |
| Right-of-use assets | 209,262 | 275,861 | 340,977 | 404,660 |
| Total assets | 66,483,081 | 72,059,317 | 77,801,012 | 84,962,888 |
| Accounts payable | 141,356 | 158,461 | 13,423 | 1,455,271 |
| Accrued expenses | 2,672,164 | 6,120,297 | 6,999,297 | 6,663,580 |
| Current portion of debt | 15,300,000 | 15,249,632 | 15,199,265 | 15,148,897 |
| Operating lease liabilities | 212,769 | 280,537 | 271,948 | 263,551 |
| Deferred collaboration revenue | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 |
| Total current liabilities | 24,326,289 | 27,808,927 | 28,483,933 | 29,531,299 |
| Operating lease liabilities, long-term | - | - | 72,536 | 143,447 |
| Long-term debt, net of current portion | - | 0 | 0 | 0 |
| Total liabilities | 24,326,289 | 27,808,927 | 28,556,469 | 29,674,746 |
| Common stock, voting, 0.001 par value 150,000,000 authorized and 60,321,068 and 60,162,773 shares issued and outstanding, respectively | 60,321 | 60,163 | 60,163 | 60,046 |
| Additional paid-in capital | 529,506,343 | 528,147,480 | 526,679,311 | 525,046,496 |
| Accumulated other comprehensive income | - | 0 | 815 | -10,995 |
| Accumulated deficit | -487,409,872 | -483,957,253 | -477,495,746 | -469,807,405 |
| Total stockholders equity | 42,156,792 | 44,250,390 | 49,244,543 | 55,288,142 |
| Total liabilities and stockholders equity | 66,483,081 | 72,059,317 | 77,801,012 | 84,962,888 |
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)